Background: Adults with elevated serum cholesterol levels are at increased risk of cognitive impairment, including both Alzheimer's disease and vascular dementia. While hypercholesterolemia likely mediates its adverse effects on cognition through a variety of mechanisms, it is unclear if its principal effects are through its contribution to atherosclerosis and subsequent chronic cerebral hypoperfusion or via other neurovascular mechanisms. It remains unclear whether lipid-lowering agents (LLAs) protect against cognitive decline. Objective: To evaluate the effects of hypercholesterolemia, subclinical atherosclerosis, and use of LLAs on odds of cognitive impairment. Design/Methods: Using cross-sectional data from a population-based cohort of older adults (n = 1711), we investigated the relationship between serum total and high-density lipoprotein (HDL) cholesterol levels, use of LLAs, and subclinical atherosclerosis (carotid intimamedia thickness [CIMT]) on odds of cognitive impairment (Mini-Mental State Examination score <24 or proxy-reported dementia). Results: Table 1 describes subject characteristics. While multivariable models showed no relationship between total and HDL cholesterol and cognition, subjects in the highest quartile of non-HDL (total minus HDL) cholesterol had an increased odds of cognitive impairment compared to those in the lowest quartile (OR 2.06, 95% CI 1.07-3.98), even after adjusting for CIMT. While statin use was associated with lower odds of cognitive impairment in unadjusted models (OR 0.57, 95% CI 0.36 to 0.89), this relationship disappeared after adjusting for vascular and lifestyle factors (OR 0.82,). Use of non-statin LLAs was not associated with better cognition. Conclusions/Relevance: These data suggest that hypercholesterolemia may mediate its adverse cognitive effects principally via neurovascular mechanisms other than atherosclerosis. Non-HDL cholesterol is a measure of many atherogenic lipoproteins and may better identify cognitive risk than total or HDL cholesterol alone. Use of LLAs was not associated with better cognition in this study, but should be tested in randomized clinical trials to best assess potential benefit. This research was supported by NIH grants AG11099, K23 AG021605, K23 AG026752 and EY096594. Objectives: The Wisconsin Registry for Alzheimer's Prevention (WRAP) was established to characterize the cognitive and health profile of a cohort of adult children of patients with Alzheimer disease (AD). An NIH funding application currently under review proposes to collect longitudinal data to (1) identify lifestyle and health variables associated with abnormal cognitive aging, (2) facilitate early detection of AD, and (3) develop strategies to reduce the risk of AD. Background: Adult children of persons with AD are at increased risk of developing AD due to hereditary, and environmental and health risk factors shared with affected parents. Prior studies of family members of persons with AD have typically included a mix of children and siblings. To our knowledge, WRAP is the first study to focus exclusively on adult children of persons with AD. To date, 572 adult children (ages 40 to 65 y at baseline) of persons with probable AD and 85 age-matched controls without a family history have undergone extensive baseline neuropsychologic testing, apolipoprotein E (APOE) genotyping, and characterization of demographic, health, and lifestyle variables. Design/Methods: This prospective study of asymptomatic middleaged adult children of persons with AD will build upon extensive baseline evaluation data by conducting a second wave of laboratory testing, structural and functional brain imaging, and neuropsychologic testing of WRAP participants and control subjects to define the pattern and predictors of cognitive change over a 4-year retest interval.
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Results: Preliminary data demonstrate that adult children of persons with AD are indeed at high risk, 47% of whom are APOE e4 carriers. At present, there are no significant baseline neuropsychologic differences between APOE e4 carriers, noncarriers and control subjects. However, WRAP e4 carriers demonstrate changes in cerebrospinal fluid AX42 levels that are suggestive of preclinical AD. On functional magnetic resonance imaging memory testing, WRAP e4 carriers exhibit significantly less hippocampal activation than e4 carriers without a family history, suggesting that an unknown factor embodied in family history is influencing the expression of e4 on brain activation. Conclusion/Relevance: Our preliminary findings are consistent with the hypothesis that middle-aged adult children of persons with AD are a particularly valuable group to follow prospectively given their increased genetic risk and current asymptomatic status in the presence of neurobiologic evidence for an increased risk of AD. The knowledge gained can be used to identify lifestyle and health variables associated with abnormal cognitive aging and development of AD, and to develop interventions that will slow disease progression in asymptomatic persons. 
